Skip to main content
Close
Home
Society of Hospital Medicine
Presented by Society of Hospital Medicine
Home
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

M. Alexander Otto

M. Alexander Otto began his reporting career early in 1999 covering the pharmaceutical industry for a national pharmacists' magazine and freelancing for the Washington Post and other newspapers. He then joined BNA, now part of Bloomberg News, covering health law and the protection of people and animals in medical research. Alex next worked for the McClatchy Company. Based on his work, Alex won a year-long Knight Science Journalism Fellowship to MIT in 2008-2009. He joined the company shortly thereafter. Alex has a newspaper journalism degree from Syracuse (N.Y.) University and a master's degree in medical science -- a physician assistant degree -- from George Washington University. Alex is based in Seattle.

News

It’s safe to skip SLNB for small, ultrasound-negative breast cancer

Author:
M. Alexander Otto
Publish date: September 27, 2023

Trial results support “the argument that sentinel node positivity is not, in and of itself, a critical parameter that determines therapeutic plans...

  • Read More

News

Debate: Should smoldering myeloma be treated?

Author:
M. Alexander Otto
Publish date: September 14, 2023

After hearing two experts debate the evidence at the SOHO annual meeting, an audience seemed swayed to treat high-risk myeloma patients.

  • Read More

News

Using JAK inhibitors for myelofibrosis

Author:
M. Alexander Otto
Publish date: September 11, 2023

Newer options are improving management of cytopenic patients.

  • Read More

News

AI mammogram screening is equivalent to human readers

Author:
M. Alexander Otto
Publish date: September 8, 2023

“That the AI system was able to match the performance of the average reader in this specialized group of mammogram readers indicates the...

  • Read More

News

CHP/CCUS: Low blood cancer risk for most patients

Author:
M. Alexander Otto
Publish date: September 8, 2023

The goal of ongoing research is to prevent CHIP/CCUS progression in higher-risk patients.

  • Read More

News

MM: Newest IKEMA results back isatuximab

Author:
M. Alexander Otto
Publish date: August 7, 2023

Adding isatuximab to carfilzomib and dexamethasone creates ‘another effective triplet’ for relapsed/refractory multiple myeloma.

  • Read More

News

RFS failed as endpoint in adjuvant immunotherapy trials

Author:
M. Alexander Otto
Publish date: July 31, 2023

“Our meta-analysis failed to find a significantly strong association between RFS and OS in RCTs of adjuvant immunotherapy,” the authors concluded...

  • Read More

News

DCIS isn’t an automatic indication for mastectomy in HER2+ BC

Author:
M. Alexander Otto
Publish date: July 31, 2023

In the largest look into the issue to date, investigators find that neoadjuvant therapy clears DCIS about half of the time.

  • Read More

News

Interrupting radiotherapy for TNBC linked to worse survival

Author:
M. Alexander Otto
Publish date: July 17, 2023

“All reasonable efforts should be made to prevent any treatment interruptions,” including “prophylactic measures to reduce the severity of...

  • Read More

News

ESMO helps hematologists assess new cancer drugs

Author:
M. Alexander Otto
Publish date: June 28, 2023

The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies...

  • Read More

News

Ibrutinib + venetoclax: High-risk features don’t lessen CLL response

Author:
M. Alexander Otto
Publish date: June 15, 2023

Expert cautions that upfront targeted therapies for CLL should be considered experimental, given the adverse events and lack of long-term follow-...

  • Read More

News

CAR-T hikes overall survival in relapsed/refractory LBCL

Author:
M. Alexander Otto
Publish date: June 9, 2023

Investigators say axi-cel should become the standard of care for second-line large B-cell lymphoma.

  • Read More

News

CLL: Venetoclax combos top first-line chemoimmunotherapy

Author:
M. Alexander Otto
Publish date: May 12, 2023

A triple-therapy combination yielded the best outcomes, but it should still be considered investigational.

  • Read More

News

“Terrific progress”: Adding blinatumomab for infant leukemia

Author:
M. Alexander Otto
Publish date: May 4, 2023

Immunotherapy plus chemotherapy improves outcomes and may soon become first-line treatment for a rare pediatric blood cancer.

  • Read More

News

Adding venetoclax improves ibrutinib outcomes in CLL

Author:
M. Alexander Otto
Publish date: January 23, 2023

A small study yields sanguine news about a combination treatment, as hematologists await phase 3 results.

  • Read More

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »
An Official Publication of the Society of Hospital Medicine

Society of Hospital Medicine
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Copyright  © 2023 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Menu Close